- Home
- EARN vs PBYI Comparison
EARN vs PBYI Comparison
Compare EARN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- PBYI
- Stock Information
- Founded
- EARN 2012
- PBYI 2010
- Country
- EARN United States
- PBYI United States
- Employees
- EARN N/A
- PBYI N/A
- Industry
- EARN Real Estate Investment Trusts
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- PBYI Health Care
- Exchange
- EARN Nasdaq
- PBYI Nasdaq
- Market Cap
- EARN 176.8M
- PBYI 126.5M
- IPO Year
- EARN 2013
- PBYI N/A
- Fundamental
- Price
- EARN $6.97
- PBYI $2.83
- Analyst Decision
- EARN Hold
- PBYI Strong Buy
- Analyst Count
- EARN 2
- PBYI 1
- Target Price
- EARN $6.00
- PBYI $7.00
- AVG Volume (30 Days)
- EARN 359.5K
- PBYI 257.4K
- Earning Date
- EARN 11-11-2024
- PBYI 10-31-2024
- Dividend Yield
- EARN 13.77%
- PBYI N/A
- EPS Growth
- EARN 102.38
- PBYI N/A
- EPS
- EARN 0.23
- PBYI 0.18
- Revenue
- EARN $18,419,000.00
- PBYI $219,143,000.00
- Revenue This Year
- EARN N/A
- PBYI N/A
- Revenue Next Year
- EARN $51.24
- PBYI N/A
- P/E Ratio
- EARN $30.04
- PBYI $15.55
- Revenue Growth
- EARN N/A
- PBYI N/A
- 52 Week Low
- EARN $5.09
- PBYI $2.13
- 52 Week High
- EARN $7.26
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- EARN 58.84
- PBYI 59.52
- Support Level
- EARN $6.73
- PBYI $2.79
- Resistance Level
- EARN $7.00
- PBYI $2.93
- Average True Range (ATR)
- EARN 0.08
- PBYI 0.12
- MACD
- EARN 0.02
- PBYI 0.04
- Stochastic Oscillator
- EARN 90.91
- PBYI 80.77
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.